Effective April 1, 2026, Prime will be removing the Metformin and Insulin step therapy requirement within the Diabetic GLP-1 UM policy. This update maintains client value while aligning with competitors and minimizing financial disruption in bids. This alignment also helps to ensure that Prime stays competitive in the market and maintain a robust financial strategy.